At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 55 enrolled
Drug / intervention
AtriCure Bipolar Systemdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AtriCure Synergy Bipolar RF Energy Lesions for Permanent Atrial Fibrillation Treatment During Concomitant On-Pump Endo/Epicardial Cardiac Surgery
In Brief
A Phase 3 clinical trial evaluating AtriCure Bipolar System for Atrial Fibrillation. Completed, enrolled 55 participants across 9 sites.
Detailed Summary
ABLATE is a prospective, non-randomized multi-center clinical trial to demonstrate the safety and effectiveness of the AtriCure Bipolar System for treating permanent atrial fibrillation during concomitant on-pump cardiac surgery.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtrial Fibrillation
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartNov 2007
First PostedNov 2007
Primary CompletionDec 2009
Study CompletionDec 2012
TodayJul 2026
First PostedNov 20, 2007
Enrollment StartNov 1, 2007
Primary CompletionDec 1, 2009
Study CompletionDec 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 18.6 years ago
Interventions
AtriCure Bipolar Systemdevice
Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System